Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cerebral disorder17.02.10.0170.000052%Not Available
Foetal death18.01.02.003; 08.04.01.0110.000227%
Haemorrhage24.07.01.002--Not Available
Pulmonary mass22.02.07.0040.000140%Not Available
Intra-abdominal haematoma24.07.02.034; 07.12.02.0050.000052%Not Available
Muscle mass15.05.03.018--Not Available
Gastrointestinal ulcer haemorrhage24.07.02.023; 07.04.04.0060.000035%Not Available
Impaired fasting glucose14.06.02.004; 05.06.02.0040.000035%Not Available
Pneumatosis intestinalis07.11.01.0430.000699%Not Available
Urine odour abnormal20.02.01.0200.000052%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.000129%Not Available
Testis cancer21.13.02.001; 16.25.03.0010.000052%Not Available
Chronic inflammatory demyelinating polyradiculoneuropathy10.04.10.004; 17.09.04.0040.000122%Not Available
Anxiety disorder19.06.01.0020.000035%Not Available
Major depression19.15.01.0030.000052%Not Available
Reflux gastritis07.08.02.0040.000035%Not Available
Toxic skin eruption12.03.01.073; 23.03.05.003; 10.01.01.0080.000087%Not Available
Metabolic disorder14.11.01.0010.000280%Not Available
Dyslipidaemia14.08.04.0150.000052%Not Available
Hypogonadism21.03.02.010; 05.05.04.0020.000035%Not Available
Retroperitoneal haematoma07.07.02.005; 24.07.01.0600.000035%Not Available
Hypoperfusion24.06.02.0190.000087%Not Available
Dermatitis psoriasiform23.03.14.0040.000035%Not Available
Skin oedema23.06.04.0010.000035%Not Available
Haemobilia24.07.01.049; 09.01.08.0090.000035%Not Available
Cerebral vasoconstriction24.04.06.025; 17.08.02.0120.000052%Not Available
Intestinal haemorrhage24.07.02.031; 07.12.03.0050.000105%Not Available
Anogenital warts23.10.01.003; 16.26.01.003; 21.10.03.004; 11.05.07.002; 07.19.04.0020.000070%Not Available
Protein-losing gastroenteropathy14.03.02.015; 07.11.01.0130.000035%Not Available
Extremity necrosis24.04.03.0120.000035%Not Available
The 25th Page    First    Pre   25 26 27 28 29    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene